Eli Lilly Overview

  • Founded
  • 1875

Founded
  • Status
  • Public

  • Employees
  • 35,000

Employees
  • Stock Symbol
  • LLY

Stock Symbol
  • Investments
  • 118

  • Share Price
  • $301.32

  • (As of Friday Closing)

Eli Lilly General Information

Description

Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products include Verzenio for cancer; Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.

Contact Information

Website
lilly.com
Ownership Status
Publicly Held
Financing Status
Corporation
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Stock Exchange
NYS
Primary Office
  • Lilly Corporate Center
  • Indianapolis, IN 46285
  • United States
+1 (317) 000-0000

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Eli Lilly Stock Performance

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$301.32 $305.79 $220.20 - $335.33 $286B 950M 2.93M $6.29

Eli Lilly Financials Summary

In Thousands,
USD
TTM 30-Jun-2022 FY 2021 31-Dec-2021 FY 2020 31-Dec-2020 FY 2019 31-Dec-2019
EV 322,141,934 277,687,151 174,970,137 140,327,287
Revenue 29,070,700 28,318,400 24,539,800 22,319,500
EBITDA 8,141,800 8,017,500 8,880,400 6,818,700
Net Income 5,691,600 5,581,700 6,193,700 8,318,400
Total Assets 47,063,600 48,806,000 46,633,100 39,286,100
Total Debt 16,813,800 16,884,700 16,595,300 15,317,200
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Eli Lilly Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Eli Lilly‘s full profile, request access.

Request a free trial

Eli Lilly Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Eli Lilly is a drug firm with a focus on neuroscience, endocrinology, cancer, and immunology. Lilly's key products inclu
Drug Discovery
Indianapolis, IN
35,000 As of 2021
000000 - 000

000000

derit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur sint occaecat cupida
000000000000000
Foster City, CA
00000 As of 0000
00.000
000000000 00.000

000000

cing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim venia
000000000000000
Valby, Denmark
0000 As of 0000
00000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Eli Lilly Competitors (7)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Gilead Sciences Formerly VC-backed Foster City, CA 00000 00.000 000000000 00.000
00000000 Corporation Valby, Denmark 0000 00000000
000 000000 00000 Private Debt Financed Bresso, Italy 0000 000.00 000000000 000.00
0000000000 0000000 Corporation Ingelheim am Rhein, Germany 00000
000000 000000 Corporation London, United Kingdom 00 00000 000000000 00000
You’re viewing 5 of 7 competitors. Get the full list »

Eli Lilly Patents

Eli Lilly Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-20220135540-A1 Polymorphs of an fxr agonist Pending 15-Oct-2020 0000000000
US-20220089563-A1 Polymorphs of an ssao inhibitor Pending 25-Aug-2020 0000000000
US-20220031957-A1 Methods and apparatus for aspects of a dose detection system module for a medication delivery device Pending 28-Jul-2020 00000000000
US-20210403547-A1 Antibodies that bind tgf-alpha and epiregulin for use in the treatment of pain Pending 26-Jun-2020 000000000
US-20210371399-A1 Trka inhibitor Pending 28-May-2020 C07D401/12
To view Eli Lilly’s complete patent history, request access »

Eli Lilly Executive Team (86)

Name Title Board Seat Contact Info
David Ricks Chief Executive Officer and Chairman of the Board
Patrik Jonsson Senior Vice President, President of Lilly USA and Chief Customer Officer
Edgardo Hernandez President & Senior Vice President
Ilya Yuffa President & Senior Vice President
Anne White Senior Vice President and President, Lilly Oncology
You’re viewing 5 of 86 executive team members. Get the full list »

Eli Lilly Board Members (22)

Name Representing Role Since
00000 00000 Eli Lilly Chief Executive Officer and Chairman of the Board 000 0000
00000 000000 Self Chairman, Directors and Corporate Governance Committee 000 0000
000000000 0000000000 00 Self Board Member 000 0000
0000000 000 Self Board Member 000 0000
000000 0000000 Self Board Member 000 0000
You’re viewing 5 of 22 board members. Get the full list »

Eli Lilly Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Eli Lilly Investments & Acquisitions (118)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000 0000000 20-Jul-2022 00000 0000 0000 Drug Discovery
00000 0000000 18-Jul-2022 00000 0000 00000 Biotechnology
00000 0000000 11-May-2022 00000 0000 000.00 Drug Discovery
000000 01-May-2022 00000 0000 0000 Drug Discovery
Arkuda Therapeutics 25-Jan-2022 Early Stage VC 0000 Drug Discovery
You’re viewing 5 of 118 investments and acquisitions. Get the full list »

Eli Lilly Subsidiaries (12)

Company Name Industry Location Founded
Prevail Therapeutics Biotechnology New York, NY 2017
000000 00000000000 Drug Discovery Cambridge, MA 0000
00000000 000000000 Drug Discovery Pasadena, CA 0000
0000 00000000 Pharmaceuticals Stamford, CT 0000
0000 00000000000 Biotechnology Redwood City, CA 0000
You’re viewing 5 of 12 subsidiaries. Get the full list »

Eli Lilly Exits (31)

Company Name Exit Date Exit Type Exit Size Status Buyers
00000 18-Jan-2021 0000 0000 Completed
  • 000 00000
00000 000000000000 05-Jan-2021 00000 00000 00 0000 Completed
  • 8 buyers
000000000 27-May-2020 00000 00000 00 00000 Completed
  • 9 buyers
00000000 13-Nov-2018 00000 00000 00 0000 Completed
  • 15 buyers
Alector 25-Jul-2018 Later Stage VC 00000 Completed
  • 20 buyers
You’re viewing 5 of 31 exits. Get the full list »